ArticlePlant biotechnology journal2025
Metabolic engineering of narrow-leafed lupin for the production of enantiomerically pure (-)-sparteine.
Article in Plant biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Characterization of two key cytochrome P450 enzymes inSynthetic and systems biotechnology · 2027Article
- Structural and mechanistic basis for the heterotetrameric benzaldehyde synthase from petunia.Science advances · 2026Article
- Lupins in the genome editing era: advances in plant cell culture, double haploid technology and genetic transformation for crop improvement.Frontiers in plant science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The protein crops known as lupins have been bred to accumulate low levels of antinutritional alkaloids, neglecting their potential as sources of valuable metabolites. Here, we engineered narrow-leafed lupin (NLL) to accumulate large amounts of a single alkaloid of industrial interest called (-)-sparteine. While (-)-sparteine is recognized as a key auxiliary molecule in chiral synthesis, its variable price and limited availability have prevented its large-scale use. We identified two enzymes that initiate the conversion of (-)-sparteine to a variety of alkaloids accumulating in NLL. The first one is a cytochrome P450 monooxygenase belonging to family 71 (CYP71D189), and the second one is a short-chain dehydrogenase/reductase (SDR1). We screened a non-GMO NLL mutant library and isolated a knockout in CYP71D189. The knockout displayed an altered metabolic profile where (-)-sparteine accounted for 96% of the alkaloid content in the seeds (GC-MS basis). The (-)-sparteine isolated from the mutant seeds was enantiomerically pure (99% enantiomeric excess). Apart from the altered alkaloid profile, the mutant did not have any noticeable phenotype. Our work demonstrates that (-)-sparteine is the precursor of most QAs in NLL and expands the current uses of NLL as a crop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.